JNJ Stock: Buy or Sell? Price Target & Forecast

JNJ Johnson & Johnson As of Sep 15, 2026

$266.32

Large-cap pharma dividend play trading at elevated multiples; strong margins, modest growth, insider selling pressure.

Setup: Defensive value with growth moderation Confidence: 65 Horizon: 3-6 months Risk: Medium Category: Large-cap Pharmaceutical

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals JNJ's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Fortress balance sheet, 3.1% dividend yield, 28.5% net margins, market leadership in oncology/immunology, M&A capability unlocks growth, inflows on AI/cybersecurity haven demand, forward P/E 24x reasonable for quality pharma.

▼ Bear Case

Trading near 52-week highs (↓5.4% from $281), trailing P/E 31x rich vs. peer averages, revenue growth slowing to 5.6% (2.7% CAGR), insider selling 54% above buying, price/FCF 33x stretched, debt-to-equity data missing raises opaque leverage concern.

Valuation

FAIRLY PRICED (near-term); RICH (medium-term) — score 62/100

Forward P/E 24.2x is defensible for large-cap pharma quality; trailing 30.8x signals market has already priced in near-term EPS upside. P/S 6.9x and P/FCF 32.9x are in upper quartile, leaving limited margin for disappointment. Dividend yield 3.1% below long-term pharma average, consistent with growth premium.

Technical Levels

Support · $260.00 (3-month moving average proxy; near 10-week chart low on recent pullback) · $250.00 (Psychological level; ~6% downside from entry; aligns with stop-loss zone) · $173.33 (52-week low; extreme downside (−35%); unlikely in base/bull case)

Resistance · $271.55 (Today's day-high; immediate session resistance) · $281.07 (52-week high; prior cycle peak; target for bull case on M&A/earnings beat) · $300.00 (Round-number psychological; bull case target for accelerated growth narrative)

RSI: Not provided by Finnhub; recent +0.28% daily move & consolidation near highs suggest neutral-to-overbought momentum short-term.

Financial Health

Score 75/100. Solid operational health (high margins, dividend stability). Balance-sheet concern: quick ratio 0.69 & missing debt-to-equity data flag potential liquidity stress or hidden leverage. Recommend monitoring quarterly 10-Q for working-capital trends & debt maturity schedule.

Catalysts

M&A deal announcement (cancer-asset focus flagged in recent news)	Next 1–3 months (probable; J&J flagged 'sweet spot' for early-stage oncology buys)	HIGH — large deal (est. $5–15B range) could accelerate revenue growth 1–2%, justify P/E expansion to 25–26x, drive +3–5% re-rating.
Q4 earnings report & 2025 guidance	Late January / early February	HIGH — any miss on revenue (5.6% growth already below peer average) or EPS could trigger 3–5% pullback; beat could support consolidation at highs.
RYBREVANT FASPRO (amivantamab + hyaluronidase) efficacy updates (WCLC 2026 data released)	Ongoing; pipeline readout potential Q1–Q2 2025	MEDIUM — positive oncology data (low treatment-related event rates flagged in recent news) could strengthen near-term sentiment; any safety flag risks 2–3% pullback.
Patent cliff / competitive intensity in key franchises	2–3 year medium-term horizon	MEDIUM-HIGH — biosimilar launches & patent expirations on legacy drugs (not detailed in news) could compress margins if pipeline growth insufficient.
Dividend increase announcement	Typically November/December annual review	LOW-MEDIUM — 3–5% annual increase likely (consistent with prior practice); modest positive tone but not material re-rating driver given current valuation.

Risk Flags

Trailing P/E 30.8x vs. forward 24.2x signals market pricing growth moderation; any earnings miss could reprice sharply.

Insider selling 1.46M shares vs. 1.39M bought (net -72k) over measured period; typically bears contrarian signal in large-cap pharma.

Quick ratio 0.69 below 1.0 threshold; reliance on working capital management & credit access suggests less balance-sheet cushion than peer perception.

Price/FCF 32.9x among highest multiples in large-cap pharma; vulnerable if free-cash-flow growth disappoints or rates remain elevated.

Revenue growth 5.6% YoY (5Y avg 2.7%) shows emerging organic deceleration; reliant on M&A ('sweet spot' deal flagged in recent news) to drive future expansion.

Dividend payout ratio 46% leaves modest room for increases without pressuring FCF; at 3.1% yield, dividend not a strong total-return driver.

See JNJ's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock JNJ free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

JNJ FAQ

Is JNJ a buy right now?

Johnson & Johnson's current read is a Defensive value with growth moderation setup with 65 confidence over a 3-6 months horizon. Valuation: FAIRLY PRICED (near-term); RICH (medium-term). See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is JNJ overvalued?

FAIRLY PRICED (near-term); RICH (medium-term) (valuation score 62/100). Forward P/E 24.2x is defensible for large-cap pharma quality; trailing 30.8x signals market has already priced in near-term EPS upside. P/S 6.9x and P/FCF 32.9x are in upper quartile, leaving limited margin for disappointment. Dividend yield 3.1% below long-term pharma average, consistent with growth premium.

What are the risks of buying JNJ?